Research Article

Development of Dorzolamide Loaded 6-O-Carboxymethyl Chitosan Nanoparticles for Open Angle Glaucoma

Ujwala Shinde, Mohammed Hadi Ahmed, and Kavita Singh

Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Mumbai, Maharashtra 400098, India

Correspondence should be addressed to Ujwala Shinde; ujwalashinde29@gmail.com

Received 16 May 2013; Accepted 21 August 2013

Academic Editor: Philippe Maincent

Copyright © 2013 Ujwala Shinde et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chitosan (CS) is a biodegradable, biocompatible, and mucoadhesive natural polymer soluble in acidic pH only and can be irritating to the eye. Objective of the study was to synthesize water soluble 6-O-carboxymethyl (OCM-CS) derivative of CS, and to develop CS and OCM-CS nanoparticles (NPs) loaded with dorzolamide hydrochloride (DRZ). CS was reacted with monochloroacetic acid (MCA) for OCM-CS synthesis and was characterized by FT-IR, DSC, and ^{13}C NMR. CS and OCM-CS NPs were prepared by ionic gelation method. Ocular irritation potential were evaluated and therapeutic efficacy was measured by reduction in intraocular pressure (IOP) in normotensive rabbits. Maximum yield was obtained when the ratio of water/isopropyl alcohol was 1/4 at 55°C. The FT-IR, DSC and ^{13}C NMR confirmed the formation of an ether linkage between hydroxyl groups of CS and MCA. The particle size and zeta potential of optimised CSNPs was 250.3 ± 2.62 nm and $+33.47 \pm 0.723$ mV, whereas those for OCM-CSNPs were 187.1 ± 2.72 nm and 30.87 ± 0.86 mV. The entrapment efficiency was significantly improved for OCM-CSNPs, compared to CSNPs. OCM-CSNPs had tailored drug release and improved bioavailability with reduction in pulse entry as compared to CSNPs. Hence, it can be concluded that DRZ loaded OCM-CSNPs would be better alternative option to available eye drops for glaucoma treatment.

1. Introduction

Open-angle glaucoma, the most common form of glaucoma, accounts for at least 90% of all glaucoma. It is caused by clogging of Schlemm's canal, develops slowly, and has a wide angle between iris and cornea. Its symptoms and damage are unnoticeable and it is a lifelong condition. The major risk factor for glaucoma is elevated IOP. Lowering IOP is currently the only proven method for reducing the risk of glaucomatous visual field loss and remains the primary goal of therapy [1].

DRZ is a carbonic anhydrase inhibitor (CAI) used in the treatment of glaucoma. Carbonic anhydrase (CA) is responsible for generation of bicarbonate anions secreted by the ciliary process into the posterior chamber of the eye. Inhibition of CA results in reduction of IOP. Orally administered CAIs, such as acetazolamide, are very effective ocular hypotensive agents but their oral administration results in systemic side effects including general malaise, depression, loss of appetite, fatigue, weight loss, gastrointestinal disturbances, parenthesis, and renal calculi [2]. Dorzolamide is reported to have 20 times higher potency than acetazolamide and is topically

active [3]. When dorzolamide solution is instilled in ocular cul de sac, common side effects observed are bitter taste in mouth, blurred vision, redness, burning and stinging upon instillation of eye drops, dryness of eyes with sensitivity to sunlight, and tearing. These side effects could be due to exposure of concentrated solution of dorzolamide to eyes and would be more severe when eye drops are instilled frequently to achieve the desired pharmacological effects.

Targeting the drug to the appropriate site of action in the eye is usually one of the greatest challenges in drug delivery because of its anatomical and physiological defense mechanisms. Ocular drug delivery systems thus compel specified criteria according to the physiological structure of the eye [4]. Conventional ocular preparations have the disadvantage of extremely low bioavailability, short precorneal residence time owing to the tear turnover, and rapid nasolacrimal drainage of the instilled drug from the tear fluid. Typically, less than 5% of the topically applied drug penetrates the cornea and reaches intraocular tissues. Frequent instillations are often required to achieve the required therapeutic effect, and this leads to escalating inconvenience and adverse effects [5]. Modified

ocular drug delivery systems like ocular inserts and *in-situ* gelling systems, though providing some advantages in terms of extended drug delivery, and could not overcome the problems of blurred vision, sticking of the eyelids, undesirable systemic absorption, and low patient acceptance [6].

Retention of a drug delivery system in front of the eye is thus desirable to circumvent the loss of an instilled drug. Thus, the goal in ocular therapeutics is to maintain an effective drug concentration at the site of action for an appropriate period, in order to achieve the expected pharmacological response [7]. The use of nanosystems/colloidal carriers is claimed to provide numerous advantages for ocular drug delivery systems, because of their ability to protect the encapsulated molecule while facilitating its transport to the different compartments of the eye. Furthermore, nanosystems can provide controlled drug delivery for extended periods of time. It offers an attractive benefit for the treatment of chronic ocular diseases like glaucoma. When the use of drug preparation by the patient is lifelong, this purportedly patient-friendly approach is of utmost significance [8]. These colloidal carriers may be applied in liquid form in the same manner as eye drop solutions. By interaction with the glycoproteins of the cornea and conjunctiva, they can form a precorneal depot, resulting in a prolonged release of the bound drug [9].

Ocular bioadhesion, specifically, refers to the capacity of certain polymers to adhere to the mucus coat covering the conjunctival and corneal surfaces of the eye by noncovalent bonds. The clearance time of bioadhesive polymeric systems is delayed as its dependence is shifted to mucus turnover rate rather than tear turnover rate. The importance of bioadhesive polymers lies in their ability to significantly improve the performance of controlled delivery systems by enhancing the means of optimum contact with the absorbing surface. This ultimately prolongs the residence of the ocular dosage form in the cul de sac, which reduces dosing frequency [10].

CS is a natural polysaccharide obtained from crustacean shells and is composed of 2-amino-2-deoxy- β -D-glucan combined with glycosidic linkages. The primary amine groups render special properties that make CS very useful in pharmaceutical applications. The nontoxicity, biodegradability, and biocompatibility make CS suitable for drug delivery [11]. The potential application of CS is hindered by its limited aqueous solubility. Thus, CS is chemically modified to improve the polymer process ability, solubility, antimicrobial activity, and the ability to interact with other substances [12]. Introducing a carboxymethyl group is the most advantageous method of increasing the solubility of chitosan at neutral and alkaline pH without affecting other important characteristics. OCM-CS is an amphiprotic ether derivative of chitosan, containing $-\text{COOH}$ and $-\text{NH}_2$ groups in the molecule, exhibit nontoxicity, biodegradability, biocompatibility, antibacterial, and antifungal activity, and has therefore received considerable attention in biomedical applications [13]. This overview enabled us to conclude that polymeric nanoparticles could serve as a best suited option in topical ocular delivery.

The present study was planned with objective to chemically modify chitosan and to develop nanoparticulate system

TABLE 1: Effect of solvent ratios on yield of OCM-CS.

Serial number	Samples	H ₂ O/IPA	Yield (%)
1	OCM-CS-1	1/9	75.39 $\pm$ 1.15
2	OCM-CS-2	0/10	48.62 $\pm$ 0.89
3	OCM-CS-3	2/8 (1/4)	89.13 $\pm$ 2.14
4	OCM-CS-4	5/5 (1/1)	78.54 $\pm$ 1.53
5	OCM-CS-5	8/2 (4/1)	16.29 $\pm$ 0.92
6	OCM-CS-6	10/0	5.68 $\pm$ 0.45

Values are expressed as mean $\pm$ standard deviation, $n = 3$.

OCM-CS: 6-O-carboxymethyl chitosan; IPA: isopropyl alcohol; H₂O: water.

from chitosan and modified chitosan capable of delivering the DRZ in a sustained manner. Thus frequent instillation of dorzolamide would be avoided which otherwise may induce toxic side effects and cellular damage at the ocular surface.

2. Materials and Methods

2.1. Chemicals and Animals. DRZ was received as a gift sample from FDC Ltd, (Mumbai, India). CS (degree of deacetylation 90% and MW 400.0 KD), sodium tripolyphosphate (TPP), agarose, and monochloroacetic acid (MCA) were purchased from Sangam Laboratories (Mumbai, India), Sigma-Aldrich (St. Louis, MO, USA), GE Biosciences (Pittsburgh, USA) and S.D. Fine Chem. Ltd (Mumbai, India), respectively. All other chemicals were of AR grade quality and used as received. Fertile White Leghorn chicken eggs were procured from Central Poultry Development Organization (Mumbai, India). Rabbits were supplied by Bombay Veterinary College (Mumbai, India).

2.2. Methods

2.2.1. Synthesis of OCM-CS. OCM-CS was synthesized as per the previously reported method with some modification [14, 15]. Briefly, CS (10 g) and sodium hydroxide (12.5 g) were added to solvent (100 mL) in a round bottom flask to alkalinize and swell at 35°C for 2 h. The solvent consisted of water and isopropyl alcohol. MCA (13 g) was dissolved in the solvent blend containing distilled water and isopropyl alcohol (IPA), added to the hydrated alkaline CS dropwise over a period of 30 min and then reacted for 4 h at 55°C. After completion of the reaction 2.5 M hydrochloric acid (HCl) was added to neutralize the reaction mass and the solvent was decanted. Ethyl alcohol (80%) was added to precipitate, desalt, and dewater the OCM-CS. The product was dried under vacuum at room temperature. The dried product was dissolved in distilled water and subjected to dialysis for 3 days, after which it was lyophilized. The OCM-CS yield was optimized by varying solvent ratios and temperature conditions (Tables 1 and 2).

2.2.2. Characterization of OCM-CS

Fourier Transformation-Infrared (FT-IR) Spectroscopy. Potassium bromide (KBr) 50 mg was thoroughly mixed with 10 mg of OCM-CS CS to prepare KBr disks with electrically operated KBr Press Model HP-15. Jasco FTIR-5300

TABLE 2: Effect of reaction temperature on yield of OCM-CS.

Serial number	Samples	Temperature (°C)	Yield (%)
1	OCM-CS-1	5	7.89 ± 0.85
2	OCM-CS-2	25	65.21 ± 1.87
3	OCM-CS-3	35	70.59 ± 1.58
4	OCM-CS-4	45	73.87 ± 1.98
5	OCM-CS-5	55	89.15 ± 3.25

Values are expressed as mean ± standard deviation, $n = 3$.
OCM-CS: 6-O-carboxymethyl chitosan.

spectrophotometer (JASCO, MD, USA) was used to obtain IR spectra of the prepared disc of OCM-CS and CS. The scanning range was 4000–400 cm^{-1} .

Differential Scanning Calorimetry. The Differential scanning calorimetry (DSC) thermograms were obtained using DSC 6220 (SII Nanotechnology, Northridge, CA, USA). Briefly, about 10 mg of sample was placed in aluminum sample pan and sealed. The samples were heated from 0°C to 500°C at a heating rate of 10°C/min using nitrogen as purge gas (20 mL/min). The DSC was earlier calibrated using standard Alumina.

^{13}C NMR Spectroscopy. The ^{13}C NMR spectrum of OCM-CS was acquired at 80°C by using a Mercury Plus 300 MHz NMR spectrometer (Varian Medical Systems, Inc., CA, USA). For acquiring the ^{13}C NMR spectra of OCM-CS, its solution was prepared in D_2O at concentration of 10 mg/mL.

Content of Free Amino Group. The content of free amino group is defined as the average number of free nitrogen atom of each saccharide unit in an OCM-CS molecule. It was measured by potentiometric titration [16].

About 0.2 g of OCM-CS, was added into 25.0 mL of standard HCl (0.1 M) solution and stirred until the sample was completely dissolved. The solution was then potentiometrically titrated with 0.1 M standard NaOH solution. According to the volume of NaOH between the second and third pH leap, the content of amino group was calculated from the formula

$$\text{Content of free amino} = \frac{(V_3 - V_2) \times C_{\text{NaOH}} \times 240.07}{W_{\text{Sample}}}, \quad (1)$$

where V_2 and V_3 are the volumes (mL) of standard NaOH solution used in the second and third pH leap, respectively, C_{NaOH} is the concentration of standard NaOH solution, W_{Sample} represents the weight (g) of the sample, and 240.07 is the average molecular weight of each saccharide unit in an OCM-CS molecule.

Degree of Substitution. Degree of substitution (DS) is the number of carboxymethyl group that binds to the glucosamine (skeleton unit) in an OCM-CS molecule. The DS of OCM-CS was determined by dissolving OCM-CS (300 mg)

in 0.1 M HCl (30 mL) and titrating with 0.1 M aqueous NaOH. The DS value was calculated as follows [17, 18]:

$$\text{DS} = \frac{161A}{(M_{\text{OCM-CS}} - 58A)}, \quad (2)$$

$$A = V_{\text{NaOH}} \cdot C_{\text{NaOH}},$$

where V_{NaOH} and C_{NaOH} were the volume and molarity of aqueous NaOH, respectively, $M_{\text{OCM-CS}}$ was the mass of OCM-CS, and 161 and 58 are the molecular weights of the glucosamine and the carboxymethyl group, respectively.

2.2.3. Preparation of OCM-CS and CS NPs. In the present study, OCM-CS and CS NPs were prepared by ionic gelation method which was induced by adding 1% w/v solutions of calcium chloride (CaCl_2) and TPP, respectively [19, 20]. Briefly, OCM-CS (4 mg/mL) was dissolved in distilled water whereas CS (4 mg/mL) was dissolved in glacial acetic acid and pH of CS solution was adjusted to 5.5 with sodium acetate buffer pH 5.5. OCM-CS and CS NPs were formed spontaneously at room temperature when CaCl_2 and TPP solutions were added to the aqueous solution of OCM-CS and CS under magnetic stirring, respectively. After complete addition of CaCl_2 and TPP, solutions were further stirred for 30 min to ensure complete gelation of NPs. Different weight ratios (1:1 to 6:1) of OCM-CS : CaCl_2 and CS : TPP were used in order to determine the weight ratio providing NPs with optimum nanosize particles. For the preparation of drug-loaded NPs, DRZ was added in the polymer solution. Different DRZ concentrations were used, 10%, 20%, 25%, 50%, and 75% (w/w) based on polymer weight, in order to study the effect of the DRZ loading on the particle size, PI, zeta potential, entrapment efficiency, and *in vitro* release profile. Every batch was prepared in triplicate and the results represent the average value. The DRZ loaded NPs were centrifuged at 30,000 rpm for 30 min at 4°C using Optima Max XP ultracentrifuge (Beckman Coulter, USA), supernatant was discarded, and pellets were resuspended in distilled and lyophilized by adding mannitol as cryoprotectant.

Particle Size PI and Zeta Potential of NPs. The particle size distribution, NPs was determined by dynamic light scattering (DLS) using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Worcestershire, UK) at 25°C. The NP dispersions were diluted in distilled and filtered water (Millex-HV Filter, 0.45 μm , Millipore, Billerica, MA, USA) up to a count rate of 50 to 300 Kcps (1000 counts per second). The data reported were particle size, evaluated as the intensity obtained from three repeat measurements, and the polydispersity index [20]. Before measurement of zeta potential, nanoparticulate dispersions were diluted with filtered 1 mM NaCl solution (Millex-HV Filter, 0.45 μm , Millipore, Billerica, MA, USA) up to a count rate of 100 to 1000 Kcps. All measurements were performed in triplicate.

Evaluation of Entrapment Efficiency of NPs. Entrapment efficiency of DRZ loaded NPs was determined according to the previously reported method [20]. For the determination of the entrapment efficiency, the NPs were first separated from

TABLE 3: Irritation scores and interpretations used in HET-CAM test.

Effect/time (min)	Score			Cumulative score	Irritation assessment
	0.5	2	5		
Hyperemia	5	3	1	0–0.9	None
Hemorrhage	7	5	3	1.0–4.9	Slight
Clotting/coagulation	9	7	5	5.0–8.9	Moderate
				9.0–21.0	Severe

the aqueous suspension medium by ultracentrifugation at 40,000 rpm for 30 min using Optima Max XP ultracentrifuge (Beckman Coulter, USA). The entrapment efficiency was determined in triplicate indirectly by analyzing the amount

of free DRZ in supernatant. The free DRZ in supernatant was quantified by validated UV spectrophotometric method at 254 nm. The entrapment efficiency of DRZ NPs was calculated as follows:

$$\text{Entrapment efficiency} = \frac{[\text{Total amount of DRZ loaded} - \text{Free DRZ in supernatant}]}{\text{Total amount of DRZ loaded}} \times 100. \quad (3)$$

In Vitro Drug Release of NPs. The *in vitro* drug release profiles of optimized, lyophilized, and sterilized DRZ loaded NPs were determined in 50 mL simulated tear fluid, pH 7.4 (STF) using dialysis bags (Himedia Laboratories, India) at 37°C under magnetic stirring. At predetermined time intervals, 5 mL aliquots were withdrawn from the medium and analyzed for DRZ by validated UV spectrometry. To determine the release behavior of free drug, *in vitro* study of DRZ solution (2% w/v) was also performed as control experiment [20]. Studies were performed in triplicates and data was analyzed for release kinetics.

In Vitro Mucoadhesion of NPs. The binding efficiency of mucin to NPs was determined by mixing 2 mL of mucin (625 µg/mL) with the same volume of NPs. NPs were previously ultra centrifuged at 40,000 rpm for 30 min and resuspended in distilled water. After incubation at 37°C for 30 min, the samples were ultracentrifuged at 40,000 rpm for 30 min. The concentration of free mucin in the supernatant was determined at 555 nm by periodic acid/Schiff (PAS) colorimetric method [21, 22]. The mucin binding efficiency of NPs was calculated from the following equation:

$$\text{Mucin binding efficiency (\%)} = \left[\frac{(C_0 - C_s)}{C_0} \right] \times 100, \quad (4)$$

where C_0 is the initial concentration of mucin used for incubation and C_s is the concentration of free mucin in the supernatant.

FT-IR Spectroscopy and DSC Analysis of NPs. IR spectra and DSC thermograms of lyophilized OCM-CS and CS NPs (without cryoprotectant) were obtained to study any possible interaction and to characterize the thermal behavior between polymers and DRZ.

Morphological Characterization of NPs. Transmission electron microscopy (TEM) was used to examine the morphology of the OCM-CSNs. TEM micrographs were obtained with Philips CM-200 (PHILIPS, The Netherlands). The sample

of OCM-CSNs (5–10 µL) was dropped onto Formvar coated copper grids. After complete drying, the sample was stained using 2% (w/v) phosphotungstic acid. Digital Micrograph and Soft Imaging Viewer software were used to perform the image capture and analysis, including particle sizing.

Ocular Irritation Potential Test. The hen's egg test on the chorioallantoic membrane (HET-CAM) is the alternative method to animal experimentation for assaying corrosives and/or severe ocular irritants, using CAM of embryonated hen's egg [23]. The HET-CAM was described by Luepke to evaluate irritant/corrosive potential and allows the study of the immediate effects of administration of the test substance on membrane of embryonated hen's egg. This method is internationally validated [24].

Fresh fertile White Leghorn hen's eggs were obtained and candled prior to use to discard nonviable or defective eggs. Eggs were placed in an incubator at $37 \pm 0.2^\circ\text{C}$ and $58 \pm 2\%$ relative humidity for 8 days. The test compounds and controls were dissolved in 2.5% (w/v) solution of agarose to reach final concentrations of 25 µg/µL (250 µg/pellet). For ease of application, pellets of these solutions were prepared by drop wise application of 10 µL on parafilm and immediately cooled to room temperature for solidification [25]. On day 9, eggs were removed from the incubator; air cell of the eggs was marked, cut, and pared off without injuring the CAM. Pellets were placed directly onto the CAM and observed for 300 seconds for sign of hemorrhage or lysis reactions on the CAM. A 0.9% (w/v) sodium chloride (NaCl) and 1% (w/v) sodium dodecyl sulfate (SDS) in distilled water were used as negative control and positive control, respectively. The whole experiment was carried out under laminar airflow cabinet at room temperature.

After the application of the test substance, the chorioallantoic blood vessels and capillaries were examined for irritant effects. The irritant effects were hyperaemia, haemorrhage and clotting at different time points after application for 5 min [26]. A time-dependent numerical score was allocated to each test substance or formulation (Table 3).

Therapeutic Efficacy Studies in Rabbits. The optimized NPs formulations were tested for their intraocular pressure lowering activity on normotensive albino rabbits (2–2.5 kg) and the results were compared to those of a marketed DRZ solution (2.0%). Various studies are reported citing normotensive rabbit as an appropriate animal model for therapeutic efficacy study [27]. The normotensive rabbit model was chosen due to its experimental feasibility and simplicity in interpretation of collected data. Institutional Animal Ethics Committee (IAEC) approved the pharmacological efficacy studies in rabbits. The animals were housed at controlled temperature ($25 \pm 2^\circ\text{C}$) and humidity ($60 \pm 5\%$), with a 12/12 h light-dark cycle. They had free access to food and water. The dispersions of sterile lyophilized NPs formulations in sterile distilled water were used in this study having a concentration of 2.0% w/v DRZ. The rabbits were divided in to three groups. Each group composed of three rabbits. Group 1, Group 2, and Group 3 received OCM-CSNPs, CSNPs, and marketed formulations, respectively. For measuring the IOP, cornea of each rabbit was anaesthetized by instilling 50 μL xylocaine (2% w/v) solution before administration of formulation. All rabbits received a single 50 μL dose of NPs and marketed formulation onto the corneal surface of rabbit's right eye. After instillation of formulation, the therapeutic efficacy of DRZ nanoparticles was assessed by measuring the IOP using a standardized tonometer (ShiØtz, Germany) [28]. IOP was measured after 30 min of drug administration and then every 1 hour over the period of 8 h. The left eye was left as a control in all the experimental animals. The ocular pressure lowering activity was expressed as average difference in IOP between the treated and control eye [29].

2.3. Statistical Analysis. Data are presented as the mean $\pm$ standard deviation. One-way analysis of variance (ANOVA) was performed followed by Dennett's multiple comparisons to test the statistical significance. The tests were performed by using GraphPad Prism version 6.01 for Windows, GraphPad Software (La Jolla CA, USA).

3. Results and Discussion

3.1. Synthesis of OCM-CS. Percentage yield of OCM-CS in IPA alone gave low yield (48.62%) which may be attributed to the fact that CS was not alkalized in the nonaqueous solvent. The use of water alone as solvent lowers the yield even more (5.68%) owing to the easy swelling of the previously formed OCM-CS in water to form jelly that coats the outside of the CS particle and inhibits the course of reaction. Therefore ratio of water/IPA was an important element for the successful completion of the reaction. The increase of the ratio of water/IPA in the reaction solvent decreases the fraction of carboxymethylation and increases the insolubility [15].

Similarly, when the effect of temperature on percent yield of OCM-CS was investigated, it was noted that the higher reaction temperature favoured the substitution of the carboxymethyl on the $-\text{OH}$ group [14]. The highest yield 89.15% was obtained at 55°C (Table 2). Hence, 55°C temperature and solvent ratio $\text{H}_2\text{O}/\text{IPA}$ of 1/4 were considered optimum.

FIGURE 1: FT-IR spectrum of (a) CS and (b) OCM-CS. Intense peak at 1734 cm^{-1} in the IR spectrum of OCM-CS signifies the presence of $-\text{COOH}$ group. Abbreviations: OCM-CS, 6-O-carboxymethyl chitosan; CS, chitosan; FT-IR, Fourier transformation-infrared.

FIGURE 2: DSC thermograms of (a) CS and (b) OCM-CS. The endothermic and exothermic event for OCM-CS appeared at higher temperatures. Abbreviations: OCM-CS, 6-O-carboxymethyl chitosan; CS, chitosan; DSC, differential scanning calorimetry.

3.2. FT-IR Spectra of OCM-CS. The basic characteristic peaks (Figure 1) of CS are at 3455 cm^{-1} ($\text{O}-\text{H}$ stretch), $2923\text{--}2867\text{ cm}^{-1}$ ($\text{C}-\text{H}$ stretch), $1598\text{--}1625\text{ cm}^{-1}$ ($\text{N}-\text{H}$ bend), and 1094 cm^{-1} ($\text{C}-\text{O}$ stretch). Compared with the peaks of CS, intense peak at 1734 cm^{-1} in the IR spectrum of OCM-CS signifies the presences of $-\text{COOH}$ group. The 1076 cm^{-1} peak is attributable to $\text{C}-\text{O}$ stretching of ether group of carboxymethyl moiety [30].

3.3. DSC Thermogram of OCM-CS. The thermograms of CS and OCM-CS were characterized by two thermal events: the first endothermic and the second exothermic (Figure 2). The endothermic event appeared as a peak centered at $125\text{--}150^\circ\text{C}$. The exothermic event appeared as a peak centered at $270\text{--}330^\circ\text{C}$ corresponding to the decomposition of

FIGURE 3: ^{13}C NMR spectrum of OCM-CS. Peak for $-\text{CH}_2$ at O-6 is intense compare to that present at O-3 and N-2. Abbreviations: OCM-CS, 6-O-carboxymethyl chitosan; C1-6, carbon atom of OCM-CS unit; C=O, carbonyl group; CH₂, mehtylene group; O-3, O-6, oxygen present at the third and the sixth carbon of OCM-CS; N-2, nitrogen present at the second carbon atom of OCM-CS.

the polymer. In contrast, both the peaks for CS appeared at lower temperatures (close to 100°C and 280°C , resp.) indicating the superior thermal stability of OCM-CS that was in accordance with the finding by Kittur et al., 2002 [31].

3.4. ^{13}C NMR Spectroscopy. Evidence supporting the successful carboxymethylation of CS was provided by the ^{13}C NMR spectrum of OCM-CS (Figure 3). The signals for $-\text{COOH}$ substituted on $-\text{OH}$ and $-\text{NH}$ were present at 173.4 and 170.1 ppm, respectively. Chemical shifts at 70.9, 69.1, and 48.3 ppm were assigned to $-\text{CH}_2\text{COOH}$ groups substituted on O-6, O-3, and N-2, indicating that there were three possible sites for the carboxymethylation of CS. On account of the signal intensity, it was concluded that the OH-6 was the major site for carboxymethylation of CS [32, 33].

3.5. Content of Free Amino Group. The content of free amino group was found to be 84.02%. V_1 and V_2 (Figure 4) represent the volume of 0.1 M NaOH needed to neutralize excess of free HCl and carboxyl group of OCM-CS, respectively. V_3 is the volume of 0.1 M NaOH required to neutralize the carboxyl group and HCl associated with NH_2 functional group of OCM-CS. Subtraction of V_2 from V_3 gives the volume of 0.1 M NaOH required to neutralize the HCl associated with the NH_2 group of OCM-CS. From the result, it was clear that almost 16% of the amino groups (84.02% free amino group) present in the saccharide unit of OCM-CS molecule were also substituted with the carboxymethyl group during the synthesis of OCM-CS from CS.

FIGURE 4: Graphical representation of potentiometric curve for content of free amino group. V_1 and V_2 represent the volume of 0.1 M NaOH needed to neutralize excess of free HCl and carboxyl group of OCM-CS. V_3 is the volume of 0.1 M NaOH required to neutralize the carboxyl group and HCl associated with NH_2 functional group of OCM-CS. Abbreviations: ΔpH , change in pH.

3.6. Degree of Substitution. The value of DS was found to be 1.1576. It signified that, apart from $-\text{OH}$ group at the sixth carbon (C_6), some of the $-\text{OH}$ group present at the third carbon (C_3) and $-\text{NH}_2$ groups present at the second carbon (C_2) of the CS were also carboxymethylated which was confirmed from the content of amino group.

3.7. Preparation of OCM-CS and CS NPs. The weight ratios between OCM-CS:CaCl₂ and CS:TPP are critical and

TABLE 4: Effect of drug loading on PS and PI of OCM-CSNs.

OCMCS : CaCl ₂ weight ratio	PS of drug loaded NPs (nm)	PI	PS of blank NPs (nm)
6 : 1	212.4 ± 0.79	0.244 ± 0.016	174.0 ± 1.29
5 : 1	325.1 ± 5.31	0.384 ± 0.008	296.0 ± 6.85
4 : 1	500.4 ± 11.88	0.444 ± 0.028	481.8 ± 14.88

Values are expressed as mean ± standard deviation, $n = 3$.

OCM-CS: 6-O-carboxymethyl chitosan; CaCl₂: calcium chloride; PS: particle size; NPs: nanoparticles; PI: polydispersity index; OCM-CSNs: 6-O-carboxymethyl chitosan nanoparticles.

TABLE 5: Effect of drug loading on PS and PI of CSNs.

CS : TPP weight ratio	PS of drug loaded NPs (nm)	PI	PS of blank NPs (nm)
6 : 1	250.3 ± 2.627	0.313 ± 0.009	247.5 ± 3.379
5 : 1	383.2 ± 3.668	0.385 ± 0.006	355.3 ± 6.102
4 : 1	490.9 ± 4.804	0.442 ± 0.030	446.7 ± 9.628

Values are expressed as mean ± standard deviation, $n = 3$.

CS: chitosan; TPP: tripolyphosphate; PS: particle size; NPs: nanoparticles; PI: polydispersity index; CSNs: chitosan nanoparticles.

controls the particle size and size distribution of the nanoparticles [19, 20]. The size characteristics have been found to affect the biological performance of NPs [34]. The changes in the PS and PI for series of OCM-CS : CaCl₂ and CS : TPP weight ratios revealed that as the concentration of crosslinkers was increased, PS and PI of NPs were increased to NPs in micron range. The increase in CaCl₂ and TPP concentration in the mixing ratio leads to agglomeration of OCM-CS and CS in NPs. The optimum OCM-CS : CaCl₂ and CS : TPP weight ratios that resulted in particles of submicron range were found to be 4 : 1, 5 : 1, and 6 : 1. These ratios were loaded with 50% DRZ and NPs were studied for PS, PI, zeta potential, and entrapment efficiency.

3.8. Particle Size and PI of NPs. Particle size distribution of DRZ loaded OCM-CSNPs varied from 212.4 ± 0.79 nm to 500.4 ± 11.88 nm with PI varying from 0.244 ± 0.016 to 0.444 ± 0.028 as the weight ratio of OCM-CS : CaCl₂ changed from 6 : 1 to 4 : 1. It was clear that by incrementing OCM-CS in the weight ratio, blank OCM-CSNPs of smaller sizes were produced (Table 4). Incorporation of the DRZ into OCM-CSNPs led to increase of their size compared with blank NPs. This could be attributed to reduction in ionic interactions between OCM-CS and CaCl₂ during formation of NPs due to the positive charge induced on DRZ molecules by ionization in distilled water (pH 7) [20]. A similar trend was observed for CSNPs (Table 5). Particle size and PI varied from 250.3 ± 2.63 to 490.9 ± 4.80 and 0.442 ± 0.030 to 0.313 ± 0.009, respectively, as the CS : TPP weight ratio of DRZ loaded CSNPs was changed from 6 : 1 to 4 : 1.

3.9. Zeta Potential of NPs. Zeta potential values varied from -18.03 ± 0.404 to -28.57 ± 0.513 as the OCM-CS : CaCl₂ weight ratio changed from 4 : 1 to 6 : 1. The negative zeta potential values for OCM-CSNPs were attributed to the presence of negatively charged carboxyl groups (COO⁻) [35]. When the proportion of OCM-CS in polymer: cross linker,

weight ratio was high the zeta potential value was also high (Table 6). The high zeta potential value demonstrated the availability of excessive anionic charged on OCM-CSNPs. The zeta potential values in all ratios indicated the moderate stability of OCM-CSNPs. In the case of CSNPs, zeta potential values were positive, indicative of protonated amino group (NH₃⁺) of CS. CSNPs followed the similar trend that with the increase of CS in CS : TPP weight ratio the positive zeta potential also increased indicating excess of NH₃⁺ (Table 7).

3.10. Evaluation of Entrapment Efficiency of NPs. The entrapment efficiency of OCM-CSNPs for 50% DRZ loading was found to be 18.13 ± 0.47, 13.71 ± 0.53, and 9.37 ± 0.36 for OCM-CS : CaCl₂ weight ratio 6 : 1, 5 : 1, and 4 : 1, respectively, (Table 6). OCM-CSNPs were formed due to ionic interactions between OCM-CS, CaCl₂, and DRZ. As the concentration of OCM-CS increased from 4 : 1 to 6 : 1, entrapment efficiency also increased owing to availability of larger number of negatively charged COO⁻ group that interacted with positively charged NH₃⁺ of DRZ. The amount of CaCl₂ required for ionic gelation of OCM-CS containing DRZ was less than that required for plain OCM-CS solution. This indicates that the binding affinity of CaCl₂ towards OCM-CS in presence of DRZ was reduced.

For CSNPs, entrapment efficiency was found to be 20.08 ± 0.87, 16.29 ± 0.61, and 10.51 ± 0.57, respectively, for 6 : 1, 5 : 1, and 4 : 1 for CS : TPP weight ratio (Table 7). In this case, there was no ionic interaction (only weak electrostatic interaction) between CS and DRZ (both positively charged at pH 5.5) but negatively charged polyanionic TPP could interact with cationic CS and preferentially with protonated DRZ. Therefore, with increased concentration of TPP in CS : TPP weight ratio from 6 : 1 to 4 : 1, the amount of DRZ available for physical entrapment with CS decreased resulting in decreased entrapment. Similar results were obtained by Singh et al. for CSNPs of brimonidine tartrate which is also protonated at the same pH [36]. Therefore, CS : TPP weight ratio 6 : 1,

TABLE 6: Effect of drug loading on zeta potential and EE of OCM-CSNs.

OCM-CS: CaCl ₂ weight ratio	Zeta potential (mV)		EE of OCM-CSNs
	DRZ loading (50%)	Blank OCM-CSNs	
6:1	-28.57 ± 0.513	-32.57 ± 0.571	18.13 ± 0.47
5:1	-24.57 ± 1.858	-27.19 ± 0.337	13.71 ± 0.53
4:1	-18.03 ± 0.404	-24.87 ± 0.259	9.37 ± 0.36

Values are expressed as mean $\pm$ standard deviation, $n = 3$.

OCM-CS: 6-O-carboxymethyl chitosan; CaCl₂: calcium chloride; NPs: nanoparticles; EE: entrapment efficiency; OCM-CSNs: 6-O-carboxymethyl chitosan nanoparticles.

TABLE 7: Effect of drug loading on zeta potential and EE of CSNs.

CS: TPP weight ratio	Zeta potential (mV)		EE of CSNs
	DRZ loading (50%)	Blank CSNs	
6:1	$+32.47 \pm 0.723$	$+28.58 \pm 0.421$	20.08 ± 0.87
5:1	$+25.33 \pm 0.404$	$+23.79 \pm 0.234$	16.29 ± 0.61
4:1	$+22.13 \pm 0.351$	$+21.58 \pm 0.347$	10.51 ± 0.57

Values are expressed as mean $\pm$ standard deviation, $n = 3$.

CS: chitosan; TPP: tripolyphosphate; EE: entrapment efficiency; NPs: nanoparticles; CSNs: chitosan nanoparticles.

with minimum amount of TPP resulted in the highest entrapment [20].

3.11. Effect of Drug Loading on Particle Size, Zeta Potential, and Entrapment Efficiency. The OCM-CS:CaCl₂ and CS:TPP weight ratios were loaded with a different polymer: DRZ and the effect on particle size, PI, zeta potential, and entrapment efficiency was studied (Table 8). For OCM-CSNPs, particle size increased with increased DRZ loading. The mean particle size varied from 181.1 ± 2.721 to 239.6 ± 3.811 nm with PI ranging from 0.209 ± 0.081 to 0.316 ± 0.029 . The negative zeta potential values changed from -31.24 ± 0.75 to -24.03 ± 0.68 as the concentration of DRZ increased. These results demonstrated that the incorporation of the DRZ into OCM-CSNPs led to a drug proportion-dependent increase of their size compared with blank NPs (Figure 5). Increased drug proportion caused an increased reduction of OCM-CS:CaCl₂ interaction, leading to increase NPs size [37], whereas no significant change in the particle size of CSNPs was observed as the drug loading was increased. The mean particle size was found to be in the range of 250.3 ± 2.627 nm with PI 0.313 ± 0.009 (Figure 6). Zeta potential values showed moderate to good stability ($+28.61 \pm 0.924$ to $+33.89 \pm 0.547$). These narrow particle size distributions with low PI and moderate zeta potential values attributed to stability of OCM-CS and CS NPs [38].

The entrapment efficiency for OCM-CSNPs was found to be 18.38 ± 0.29 , 18.13 ± 0.47 , 34.87 ± 0.33 , and 25.29 ± 0.56 as the amount of DRZ decreased from 75% to 10% of DRZ loading (Table 8). DRZ exhibits two distinct pK_a values, 6.35 (pK_{a1}) and 8.5 (pK_{a2}) corresponding to the protonated secondary amino group and negatively charged sulfonamide group, respectively [39]. It exhibits a cationic form at and below pH 6.4 and anionic form, at and above pH 8.5. The largest fraction of unionized form exists at pH right between

FIGURE 5: Effect of drug loading on OCM-CS:CaCl₂ weight ratio of 6:1. Values are expressed as mean $\pm$ standard deviation, $n = 3$. Abbreviations: OCM-CS, 6-O-carboxymethyl chitosan; CaCl₂, calcium chloride; PS, particle size; EE, entrapment efficiency; DRZ, dorzolamide hydrochloride.

FIGURE 6: Effect of drug loading on CS:TPP weight ratio of 6:1. Values are expressed as mean $\pm$ standard deviation, $n = 3$. Abbreviations: CS, chitosan; TPP, tripolyphosphate; PS, particle size; EE, entrapment efficiency; DRZ, dorzolamide hydrochloride.

TABLE 8: Effect of drug loading on OCM-CS : CaCl₂ weight ratio of 6 : 1.

DRZ loading (%)	PS (nm)	PI	Zeta potential (mV)	EE of OCM-CSNs
Blank OCM-CSNs	174.0 ± 1.29	0.269 ± 0.021	-32.57 ± 0.57	—
10%	181.1 ± 2.19	0.209 ± 0.081	-31.24 ± 0.75	25.29 ± 0.56
20%	187.1 ± 2.72	0.219 ± 0.006	-30.87 ± 0.86	34.87 ± 0.33
50%	212.4 ± 3.21	0.244 ± 0.016	-28.57 ± 0.51	18.13 ± 0.47
75%	239.6 ± 3.81	0.316 ± 0.029	-24.03 ± 0.68	18.38 ± 0.29

Values are expressed as mean ± standard deviation, $n = 3$.

OCM-CS: 6-O-carboxymethyl chitosan; CaCl₂: calcium chloride; PS: particle size; NPs: nanoparticles; PI: polydispersity index; EE: entrapment efficiency; OCM-CSNs: 6-O-carboxymethyl chitosan nanoparticles; DRZ: dorzolamide hydrochloride.

TABLE 9: Effect of drug loading on CS : TPP weight ratio of 6 : 1.

DRZ loading (%)	PS (nm)	PI	Zeta potential (mV)	EE of CSNs
Blank CSNs	247.5 ± 3.379	0.259 ± 0.009	27.58 ± 0.42	—
25%	249.5 ± 3.866	0.267 ± 0.005	+28.61 ± 0.92	17.83 ± 0.61
50%	250.3 ± 2.627	0.313 ± 0.009	+33.47 ± 0.72	20.28 ± 0.48
75%	244.4 ± 1.735	0.323 ± 0.040	+33.89 ± 0.55	19.81 ± 0.37

Values are expressed as mean ± standard deviation, $n = 3$.

CS: chitosan; TPP: tripolyphosphate; PS: particle size; NPs: nanoparticles; PI: polydispersity index; EE: entrapment efficiency; CSNs: chitosan nanoparticles; DRZ: dorzolamide hydrochloride.

the two pK_a values. The aqueous solubility of DRZ is a function of ionization constant (pK_a) of the drug molecule. The pH solubility profile of DRZ exhibits lowest solubility between the two pK_a values. OCM-CS when dissolved in distilled water exhibited a pH of 7.4 ± 0.2 . At this pH range, DRZ exhibited minimal solubility owing to its unionized form and the drug was protonated as the pH was below 8.5, increasing its soluble fraction [39]. When the pH of OCM-CS was lowered at and below 6.4, it resulted in precipitation of the polymer [15]. When the DRZ loading increased from 20–75%, the amount of DRZ entrapped decreased owing to its insolubility and unionized form. For this reason the entrapment efficiency of OCM-CSNPs at lower DRZ loading was higher. About 20% DRZ loaded NPs resulted in the highest entrapment and was selected as optimized. The hydrophilicity of DRZ poses difficulty in achieving high entrapment as it can easily come to the aqueous phase outside [40]. At higher DRZ concentration entrapment efficiency was reduced because the drug tends to precipitate. Considering all these factors, concentration of OCM-CS and DRZ was optimized so as to give better entrapment and desired size. The entrapment efficiency for CSNPs was found to be 17.83 ± 0.61 , 20.28 ± 0.48 , and 19.81 ± 0.37 as the amount of DRZ loading was increased from 25% to 75% (Table 9).

3.12. In Vitro Drug Release of NPs. The *in vitro* release profiles of DRZ loaded OCM-CSNs were compared with those of DRZ from aqueous solution (Figure 7). The release profile for OCM-CSNPs followed a biphasic pattern, characterized by initial burst release followed by a prolonged release [19]. The burst release lasted for 60 min, releasing 30% to 35% drug. This initial burst release could be due to rapid dissolution of DRZ adsorbed on the surface of OCM-CSNs. After the initial burst release period, release rate was reduced and that could be due to diffusion of the drug through OCM-CSNs matrix.

FIGURE 7: Drug release profile of OCM-CSNPs. Values are expressed as mean ± standard deviation, $n = 3$. Abbreviations: OCM-CSNPs, 6-O-carboxymethyl chitosan nanoparticles; DRZ, dorzolamide hydrochloride.

The release was sustained up to 8 h. CSNPs also followed biphasic release pattern with burst release of 30 min duration releasing 30% to 35% of drug and sustained release period of 4 h (Figure 8) [36].

3.13. FT-IR Spectroscopy of NPs. In blank OCM-CSNPs, the peak at 1734 cm^{-1} shifted to lower values indicating an ionic interaction of $-\text{COOH}$ with Ca^{+2} ion (Figure 9). This

FIGURE 8: Drug release profile of CSNPs. Values are expressed as mean $\pm$ standard deviation, $n = 3$. Abbreviations: CSNPs, chitosan nanoparticles; DRZ, dorzolamide hydrochloride.

FIGURE 9: FT-IR spectra of (a) DRZ loaded OCM-CSNPs, (b) Blank OCM-CSNPs, and (c) DRZ powder. DRZ showed a strong absorbance at 3372 cm^{-1} attributed to the primary amino group. The same peak in OCM-CSNPs disappeared that was a clear indication and that the NH_2^+ of DRZ interacted strongly with $-\text{COOH}$ of OCM-CS. Abbreviations: OCM-CSNPs, 6-*O*-carboxymethyl chitosan nanoparticles; DRZ, dorzolamide hydrochloride; FT-IR, Fourier transformation-infrared.

interaction reduced OCM-CS solubility and was responsible for OCM-CS separation from the solution in the form of NPs. When DRZ entrapped into the OCM-CSNPs, the peak at 1734 cm^{-1} shifted to lower values indicating an ionic interaction of $-\text{COOH}$ with NH_2^+ of DRZ. DRZ had a strong absorbance at 3372 cm^{-1} attributed to the primary amino

FIGURE 10: FT-IR spectra of (a) DRZ loaded CSNPs, (b) blank CSNPs, and (c) DRZ powder. The broadened peak in the range $3300\text{--}3400\text{ cm}^{-1}$ was due to overlap of the primary amino and hydroxyl peaks. The peaks of DRZ at 1537 and 1344 cm^{-1} were visible in DRZ loaded CSNPs, a clear indication that no ionic interaction occurred between the DRZ and CS and the entrapment of DRZ was merely of a physical type. Abbreviations: CSNPs, chitosan nanoparticles; DRZ, dorzolamide hydrochloride; FT-IR, Fourier transformation infrared.

group. The same peak in OCM-CSNPs was disappeared and that was a clear indication that the NH_2^+ of DRZ interacted strongly with $-\text{COOH}$ of OCM-CS.

For CSNPs, no significant changes in the IR spectrum of the DRZ and DRZ loaded CSNPs occurred (Figure 10). The broadened peak in the range of $3300\text{--}3400\text{ cm}^{-1}$ was due to overlap of the primary amino and hydroxyl peaks. The peaks of DRZ at 1589 , 1537 , and 1344 cm^{-1} were visible in DRZ loaded CSNPs, a clear indication that no ionic interaction occurred between the DRZ and CS and the entrapment of DRZ was merely of a physical type [20].

3.14. DSC Analysis of NPs. DSC data allow identification and characterization of a drug substance through the melting temperature and heat of fusion, in case of crystalline substances. Polymorphic forms can also be identified by DSC by virtue of their different melting temperature. Thermogram (Figure 11) for blank OCM-CSNPs showed a shift in endotherm value indicating interaction of OCM-CS with CaCl_2 . Also the thermogram showed a shift in endotherm when DRZ was loaded showing a strong interaction of DRZ with OCM-CS, whereas DRZ loaded CSNPs showed the prominent endotherm of DRZ indicating weak interaction of DRZ with CS (Figure 12).

3.15. In Vitro Mucoadhesion of NPs. OCM-CSNPs had higher mucin binding efficiency compared to CSNPs (Table 10).

FIGURE 11: DSC thermograms of (a) DRZ loaded OCM-CSNPs, (b) Blank OCM-CSNPs, and (c) DRZ powder. Thermogram showed a shift in endotherm when DRZ was loaded showing a strong interaction of DRZ with OCM-CS. Abbreviations: OCM-CSNPs, 6-*O*-carboxymethyl chitosan nanoparticles; DRZ, dorzolamide hydrochloride; DSC, differential scanning calorimetry.

FIGURE 12: DSC thermograms of (a) DRZ loaded CSNPs, (b) Blank CSNPs and (c) DRZ powder. DRZ loaded CSNPs showed the prominent endotherm of DRZ indicating weak interaction of DRZ with CS. Abbreviations: CSNPs, chitosan nanoparticles; DRZ, dorzolamide hydrochloride; DSC, differential scanning calorimetry.

OCM-CS is an amphiprotic ether derivative which contains both the $-\text{COO}^-$ and $-\text{NH}_3^+$ groups [30, 41]. OCM-CSNPs spontaneously adsorbed on the surface of the mucin, due to electrostatic attraction between the positively charged amino groups of OCM-CS and the negatively charged sialic acid group of mucin. Apart from ionic interaction, a strong hydrogen bonding was present due to hydrophilic carboxylic acid group [42, 43].

The blank OCM-CSNPs had the highest mucoadhesion. After drug loading, the mucoadhesive strength of OCM-CSNPs decreased owing to increased particle size of drug

FIGURE 13: TEM photograph of DRZ loaded OCM-CSNPs. Bar 200 nm. Abbreviations: OCM-CSNPs, 6-*O*-carboxymethyl chitosan nanoparticles; DRZ, dorzolamide hydrochloride; TEM, transmission electron microscopy.

TABLE 10: Mucin binding efficiency of NPs.

Sr. no.	Formulation	Mucin binding efficiency (%)
1	OCM-CSNs (blank)	49.6 ± 0.68
2	CSNs (blank)	41.6 ± 0.87
3	DRZ loaded OCM-CSNs	37.76 ± 0.92
4	DRZ loaded CSNs	28.16 ± 0.46

Values are expressed as mean $\pm$ standard deviation, $n = 3$.

NPs: nanoparticles; OCM-CSNs: 6-*O*-carboxymethyl chitosan nanoparticles; CSNs: chitosan nanoparticles; DRZ: dorzolamide hydrochloride.

loaded NPs as compared to blank NPs [44]. An increase in NPs size would decrease the adsorption of mucin on NPs surface (specific surface area decreases with increase in particle size), leading to decreased mucoadhesive strength of NPs.

A similar trend was followed by CSNPs, with blank NPs being more mucoadhesive than the drug loaded NPs. The mucoadhesive strength of CSNPs was less compared to OCM-CSNs.

3.16. Morphological Characterization of NPs. TEM image of DRZ loaded OCM-CSNPs showed spherical shaped NPs (Figure 13). Discrete structure of the NPs could be attributed to negative surface charge. TEM image showed that the particle size ranged between 200 and 300 nm approximately which was in accordance with the particle size determined using DLS.

3.17. Ocular Irritation Potential Test. Figure 14 outlines the effects of control and test substances after 5 min of pellet application on the CAMs. Only embryos having intact yolk and viable CAM were further incubated to day 9. Nine-day old CAMs were utilised for application of the pellets of control test substances. The temperature and relative humidity were kept at $37 \pm 0.2^\circ\text{C}$ and $58 \pm 2\%$ RH. These were found to be the optimum conditions for CAM growing [23].

Figure 15 shows the cumulative HET-CAM scores for the controls, prepared NPs formulations. The average cumulative scores calculated for OCM-CSNs, 0.4% w/v OCM-CS and 0.9% NaCl were found to be <0.9 . These results revealed that

FIGURE 14: Vascular responses of control and test compound/formulations in the HET-CAM test (a) 0.9% NaCl, (b) 1% SDS, (c) 0.4% OCM-CS, and (d) OCM-CSNPs. Arrow mark in the figure indicate agarose pellet. Abbreviations: OCM-CS, 6-*O*-carboxymethyl chitosan; OCM-CSNPs, 6-*O*-carboxymethyl chitosan nanoparticles; NaCl, sodium chloride; SDS, sodium dodecyl sulphate; HET-CAM, hen's egg test chorioallantoic membrane.

these test substances are practically nonirritant when applied to the surface of the CAM. In contrast, CSNPs were slightly irritant with a cumulative score of 1.2 ± 0.25 , which could be attributed to acidic pH. A solution of 1% w/v CaCl_2 was found to be strongly irritant whereas OCM-CS NPs showed no irritation. It is likely that the amount of CaCl_2 in OCM-CSNPs was insufficient to produce an irritant effect. Another possible explanation could be that CaCl_2 molecules are involved in interaction and bound to polymer and not present in free form, which is likely to reduce their interaction with the ocular surface.

3.18. Therapeutic Efficacy Studies in Rabbits. The values of the reduction in IOP (mm of Hg) in normotensive albino rabbits

after instillation of a 50 μL dose of each NPs formulation as a function of time were compared to marketed formulation [45]. It was observed that the IOP lowering activity of marketed formulation reached to maximum value of 2.87 mm of Hg within 2 hr after instillation. This effect markedly decreased and abolished completely within 4 h whereas NPs formulation produced a significant sustained reduction in IOP. DRZ loaded OCM-CSNPs showed pharmacological effect that was sustained up to 8 h. The peak effect was observed at the 4th hour with reduction of IOP value by 2.19 mm of Hg, which was less than marketed formulation owing to slow release of drug from NPs compared to marketed formulation, whereas DRZ loaded CSNPs showed pharmacological effect, which was sustained up to 6 h.

FIGURE 15: Cumulative HET-CAM scores of controls and test formulations. Values are expressed as mean $\pm$ standard deviation, $n = 5$. Abbreviations: HET-CAM, hen's egg test chorioallantoic membrane; NaCl, sodium chloride; SDS, sodium dodecyl sulphate; CaCl₂, calcium chloride; DRZ, dorzolamide hydrochloride; OCM-CS, 6-*O*-carboxymethyl chitosan; OCM-CSNs, 6-*O*-carboxymethyl chitosan nanoparticles; CSNs, chitosan nanoparticles.

FIGURE 16: (a) Comparative therapeutic efficacy study of the DRZ loaded OCM-CSNPs, CSNPs, marketed formulation and control. (b) Application of ANOVA to efficacy data. Values are expressed as mean $\pm$ standard deviation, $n = 3$. Abbreviations: DRZ, dorzolamide hydrochloride; OCM-CSNs, 6-*O*-carboxymethyl chitosan nanoparticles; CSNPs, chitosan nanoparticles; ANOVA, analysis of variance.

The peak effect was observed at the third hour with reduction of IOP value by 1.91 mm of Hg. As shown in Figure 16, developed OCM-CSNPs and CSNPs formulations showed statistically significant response when compared to the control

group. Marketed formulation being solution showed pulse effect due to immediate availability of drug in large concentration. In case of NPs, drug was embedded/crosslinked in polymer matrix; large concentration of drug was not available

immediately to produce the pulse effect. The prolonged duration of action was due to increased mucoadhesion of OCM-CS that interact with mucin effectively compared to CS. The mucoadhesion phenomenon is independent of tear turnover rate and depends on the mucus turnover rate that is generally more than 15 h.

Hence, developed formulation of DRZ loaded OCM-CSNPs and CSNPs was found to be effective in lowering the IOP of eye when compared to marketed formulation. Thus, OCM-CSNPs showed better efficacy than CSNPs, which was attributed to better mucoadhesion of OCM-CS.

4. Conclusion

In this study, OCM-CS was successfully synthesized from CS and characterized. DRZ loaded NPs were fabricated using OCMCS:CaCl₂ and CS:TPP weight ratio of 6:1, respectively, by ionic gelation technique. 20% and 50% DRZ loading showed the highest entrapment efficiency for OCM-CSNs and CSNs, respectively. Entrapment efficiency of DRZ with synthesized OCM-CS improved by 14% compared to CS. *In vitro* release profile showed sustained release over the period of 8 h for OCM-CSNP. *In vitro* mucoadhesion studies showed enhanced mucoadhesion of OCM-CSNPs compared to CSNPs. Prepared OCM-CSNPs were nonirritant when tested by HET-CAM. *In vivo* studies of DRZ loaded OCM-CSNPs exhibited a promising prolonged antiglaucoma effect without pulse entry as compared to CSNPs. The resultant OCM-CSNPs had better entrapment, tailored drug release, and improved bioavailability with reduction in pulse entry as compared to CSNPs. Hence it can be concluded that DRZ loaded OCM-CSNPs is better and efficacious alternative to conventional eye drops for the anti-glaucoma activity.

Conflict of interests

The authors declare that they have no conflict of interests in this work.

Acknowledgments

The authors are thankful to TIFR, Mumbai, India for X-ray diffraction, Nair Hospital, Mumbai, India for HET-CAM and IIT Bombay, India for TEM studies.

References

- [1] J. B. Soltau and T. J. Zimmerman, "Changing paradigms in the medical treatment of glaucoma," *Survey of Ophthalmology*, vol. 47, no. 4, pp. S2–S5, 2002.
- [2] N. Pfeiffer, "Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor," *Survey of Ophthalmology*, vol. 42, no. 2, pp. 137–151, 1997.
- [3] M. F. Sugrue, "The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor," *Journal of Ocular Pharmacology and Therapeutics*, vol. 12, no. 3, pp. 363–376, 1996.
- [4] N. Li, C. Zhuang, M. Wang, X. Sun, S. Nie, and W. Pan, "Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery," *International Journal of Pharmaceutics*, vol. 379, no. 1–2, pp. 131–138, 2009.
- [5] U. A. Shinde, S. Jaykumar, N. Hema, and S. Kavita, "Eudragit RL 100 based microspheres for ocular administration of azelastine hydrochloride," *Journal of Microencapsulation*, vol. 29, no. 6, pp. 511–519, 2012.
- [6] Y. Ali and K. Lehmussaari, "Industrial perspective in ocular drug delivery," *Advanced Drug Delivery Reviews*, vol. 58, no. 11, pp. 1258–1268, 2006.
- [7] C. Bucolo, A. Maltese, and F. Drago, "When nanotechnology meets the ocular surface," *Expert Review of Ophthalmology*, vol. 3, no. 3, pp. 325–332, 2008.
- [8] M. Hamidi, A. Azadi, and P. Rafiei, "Hydrogel nanoparticles in drug delivery," *Advanced Drug Delivery Reviews*, vol. 60, no. 15, pp. 1638–1649, 2008.
- [9] K. Langer, E. Mutschler, G. Lambrecht et al., "Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part III: evaluation as drug delivery system for ophthalmic applications," *International Journal of Pharmaceutics*, vol. 158, no. 2, pp. 219–231, 1997.
- [10] R. C. Nagarwal, S. Kant, P. N. Singh, P. Maiti, and J. K. Pandit, "Polymeric nanoparticulate system: a potential approach for ocular drug delivery," *Journal of Controlled Release*, vol. 136, no. 1, pp. 2–13, 2009.
- [11] A. Dev, J. C. Mohan, V. Sreeja et al., "Novel carboxymethyl chitin nanoparticles for cancer drug delivery applications," *Carbohydrate Polymers*, vol. 79, no. 4, pp. 1073–1079, 2010.
- [12] R. Jayakumar, M. Prabakaran, S. V. Nair, S. Tokura, H. Tamura, and N. Selvamurugan, "Novel carboxymethyl derivatives of chitin and chitosan materials and their biomedical applications," *Progress in Materials Science*, vol. 55, no. 7, pp. 675–709, 2010.
- [13] A. Anitha, S. Maya, N. Deepa et al., "Efficient water soluble O-carboxymethyl chitosan nanocarrier for the delivery of curcumin to cancer cells," *Carbohydrate Polymers*, vol. 83, no. 2, pp. 452–461, 2011.
- [14] N. K. Patel and V. K. Sinha, "Synthesis, characterization and optimization of water-Soluble chitosan derivatives," *International Journal of Polymeric Materials*, vol. 58, no. 11, pp. 548–560, 2009.
- [15] X.-G. Chen and H.-J. Park, "Chemical characteristics of O-carboxymethyl chitosans related to the preparation conditions," *Carbohydrate Polymers*, vol. 53, no. 4, pp. 355–359, 2003.
- [16] D. Fu, B. Han, W. Dong, Z. Yang, Y. Lv, and W. Liu, "Effects of carboxymethyl chitosan on the blood system of rats," *Biochemical and Biophysical Research Communications*, vol. 408, no. 1, pp. 110–114, 2011.
- [17] R. A. A. Muzzarelli, F. Tanfani, M. Emanuelli, D. P. Pace, E. Chirurazzi, and M. Piani, "Sulfated N-(carboxymethyl)chitosans: novel blood anticoagulants," *Carbohydrate Research*, vol. 126, no. 2, pp. 225–231, 1984.
- [18] J. Du and Y.-L. Hsieh, "Nanofibrous membranes from aqueous electrospinning of carboxymethyl chitosan," *Nanotechnology*, vol. 19, no. 12, Article ID 125707, 9 pages, 2008.
- [19] X. Shi, Y. Du, J. Yang, B. Zhang, and L. Sun, "Effect of degree of substitution and molecular weight of carboxymethyl chitosan nanoparticles on doxorubicin delivery," *Journal of Applied Polymer Science*, vol. 100, no. 6, pp. 4689–4696, 2006.
- [20] S. Papadimitriou, D. Bikiaris, K. Avgoustakis, E. Karavas, and M. Georgarakis, "Chitosan nanoparticles loaded with dorzolamide and pramipexole," *Carbohydrate Polymers*, vol. 73, no. 1, pp. 44–54, 2008.

- [21] E. Karavas, E. Georgarakis, and D. Bikiaris, "Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics," *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 64, no. 1, pp. 115–126, 2006.
- [22] P. He, S. S. Davis, and L. Illum, "In vitro evaluation of the mucoadhesive properties of chitosan microspheres," *International Journal of Pharmaceutics*, vol. 166, no. 1, pp. 75–88, 1998.
- [23] N. P. Luepke, "Hen's egg chorioallantoic membrane test for irritation potential," *Food and Chemical Toxicology*, vol. 23, no. 2, pp. 287–291, 1985.
- [24] W. Steiling, M. Bracher, P. Courtellemont, and O. De Silva, "The HET-CAM, a useful in vitro assay for assessing the eye irritation properties of cosmetic formulations and ingredients," *Toxicology in Vitro*, vol. 13, no. 2, pp. 375–384, 1999.
- [25] L. Krenn and D. H. Paper, "Inhibition of angiogenesis and inflammation by an extract of red clover (*Trifolium pratense* L.)," *Phytomedicine*, vol. 16, no. 12, pp. 1083–1088, 2009.
- [26] H. Abdelkader, S. Ismail, A. Kamal, and R. G. Alany, "Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery," *Journal of Pharmaceutical Sciences*, vol. 100, no. 5, pp. 1833–1846, 2011.
- [27] I. P. Kaur, A. Garg, A. K. Singla, and D. Aggarwal, "Vesicular systems in ocular drug delivery: an overview," *International Journal of Pharmaceutics*, vol. 269, no. 1, pp. 1–14, 2004.
- [28] H. O. Ammar, H. A. Salama, M. Ghorab, and A. A. Mahmoud, "Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride," *AAPS PharmSciTech*, vol. 10, no. 3, pp. 808–819, 2009.
- [29] J.-Y. Winum, A. Casini, F. Mincione et al., "Carbonic anhydrase inhibitors: *N*-(*p*-sulfamoylphenyl)- α -D- glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits," *Bioorganic and Medicinal Chemistry Letters*, vol. 14, no. 1, pp. 225–229, 2004.
- [30] X. Fei Liu, Y. Lin Guan, D. Zhi Yang, Z. Li, and K. De Yao, "Antibacterial action of chitosan and carboxymethylated chitosan," *Journal of Applied Polymer Science*, vol. 79, no. 7, pp. 1324–1335, 2001.
- [31] F. S. Kittur, K. V. H. Prashanth, K. U. Sankar, and R. N. Tharanathan, "Characterization of chitin, chitosan and their carboxymethyl derivatives by differential scanning calorimetry," *Carbohydrate Polymers*, vol. 49, no. 2, pp. 185–193, 2002.
- [32] L. Chen, Y. Du, and X. Zeng, "Relationships between the molecular structure and moisture-absorption and moisture-retention abilities of carboxymethyl chitosan—II. Effect of degree of deacetylation and carboxymethylation," *Carbohydrate Research*, vol. 338, no. 4, pp. 333–340, 2003.
- [33] M. Rinaudo, P. Le Dung, C. Gey, and M. Milas, "Substituent distribution on *O,N*-carboxymethylchitosans by ^1H and ^{13}C n.m.r," *International Journal of Biological Macromolecules*, vol. 14, no. 3, pp. 122–128, 1992.
- [34] Y. Pan, Y.-J. Li, H.-Y. Zhao et al., "Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo," *International Journal of Pharmaceutics*, vol. 249, no. 1–2, pp. 139–147, 2002.
- [35] A. Anitha, V. V. D. Rani, R. Krishna et al., "Synthesis, characterization, cytotoxicity and antibacterial studies of chitosan, *O*-carboxymethyl and *N,O*-carboxymethyl chitosan nanoparticles," *Carbohydrate Polymers*, vol. 78, no. 4, pp. 672–677, 2009.
- [36] K. H. Singh and U. A. Shinde, "Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane," *Pharmazie*, vol. 66, no. 8, pp. 594–599, 2011.
- [37] D.-G. Kim, Y.-I. Jeong, C. Choi et al., "Retinol-encapsulated low molecular water-soluble chitosan nanoparticles," *International Journal of Pharmaceutics*, vol. 319, no. 1–2, pp. 130–138, 2006.
- [38] P. Calvo, C. Remuñán-López, J. L. Vila-Jato, and M. J. Alonso, "Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers," *Journal of Applied Polymer Science*, vol. 63, no. 1, pp. 125–132, 1997.
- [39] H. H. Sigurdsson, E. Stefánsson, E. Gudmundsdóttir, T. Eysteinnsson, M. Thorsteinsdóttir, and T. Loftsson, "Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration," *Journal of Controlled Release*, vol. 102, no. 1, pp. 255–262, 2005.
- [40] K. S. Snima, R. Jayakumar, A. G. Unnikrishnan, S. V. Nair, and V.-K. Lakshmanan, "O-Carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells," *Carbohydrate Polymers*, vol. 89, no. 3, pp. 1003–1007, 2012.
- [41] L. Zhang, J. Guo, J. Zhou, G. Yang, and Y. Du, "Blend membranes from carboxymethylated chitosan/alginate in aqueous solution," *Journal of Applied Polymer Science*, vol. 77, no. 3, pp. 610–616, 2000.
- [42] M. R. Jimenez-Castellanos, H. Zia, and C. T. Rhodes, "Mucoadhesive drug delivery systems," *Drug Development and Industrial Pharmacy*, vol. 19, no. 1–2, pp. 143–194, 1993.
- [43] A. Ahuja, R. K. Khar, and J. Ali, "Mucoadhesive drug delivery systems," *Drug Development and Industrial Pharmacy*, vol. 23, no. 5, pp. 489–515, 1997.
- [44] B. Petit, K. Bouchemal, C. Vauthier, M. Djabourov, and G. Ponchel, "The counterbalanced effect of size and surface properties of chitosan-coated poly(isobutylcyanoacrylate) nanoparticles on mucoadhesion due to pluronic F68 addition," *Pharmaceutical Research*, vol. 29, no. 4, pp. 943–952, 2012.
- [45] K. H. Singh and U. A. Shinde, "Development and evaluation of novel polymeric nanoparticles of brimonidine tartrate," *Current Drug Delivery*, vol. 7, no. 3, pp. 244–251, 2010.